Bioprocess Technology Global Market Report 2024

The bioprocess technology market size has grown rapidly in recent years. It will grow from $21.9 billion in 2023 to $25.62 billion in 2024 at a compound annual growth rate (CAGR) of 17.0%. The historical growth in bioprocessing technology can be attributed to several factors, including the expansion of the biopharmaceutical industry, the escalation in chronic diseases, supportive regulatory frameworks, heightened research and development efforts, and the global spread of biopharmaceutical production. These elements collectively contributed to the advancements and wider adoption of bioprocessing technologies over the period.

The bioprocess technology market size is expected to see rapid growth in the next few years. It will grow to $45.04 billion in 2028 at a compound annual growth rate (CAGR) of 15.1%. In the upcoming forecast period, the growth of bioprocessing technology is anticipated to be driven by several factors, such as the rise of single-use bioprocessing, advancements in cell and gene therapies, a greater focus on sustainable bioprocessing practices, increased outsourcing of bioprocessing services, and preparedness for global pandemics. Key trends projected during this period include the widespread adoption of single-use bioprocessing, the development of continuous bioprocessing techniques, the integration of advanced analytics and real-time process monitoring, the progression of personalized medicine and cell therapies, strategic partnerships, and the advancement of gene editing technologies. These trends are expected to significantly influence and shape the landscape of bioprocessing technology in the forecasted period.

The bioprocess technology market is expected to experience growth driven by the increasing demand from healthcare industries. Healthcare industries encompass organizations providing medical and healthcare-related products, services, and technologies. Bioprocess technology, utilizing living cells to produce therapeutic proteins, vaccines, and other biologics, plays a crucial role in the manufacturing of biopharmaceuticals and healthcare products. In 2021, health spending in the U.S. rose by 2.7%, reaching $4.3 trillion, or $12,914 per capita, as reported by the American Medical Association (AMA). Hospital care constituted 31.1% of total spending, with physician services, clinical services, and home health care accounting for 24%. This growing demand from healthcare industries is a key driver propelling the growth of the bioprocess technology market.

The rising prevalence of chronic diseases is anticipated to further fuel the growth of the bioprocess technology market. Chronic diseases, lasting three months or more and potentially worsening over time, are a significant focus for bioprocess technology. The technology contributes to the development and production of gene therapies, vaccines, cell culture and fermentation, and monoclonal antibody production aimed at addressing chronic diseases, thereby advancing medicine and enhancing the quality of life for individuals. According to the National Library of Medicine, the number of people in the U.S. aged 50 and older with at least one chronic condition is projected to increase by 99.5% to 142.66 million by 2050. Additionally, the World Health Organization (WHO) reported in September 2022 that 74% of all deaths globally are caused by noncommunicable diseases (NCDs) or chronic diseases, amounting to 41 million deaths annually. The increasing prevalence of chronic diseases is a significant driver for the growth of the bioprocess technology market.

Major companies in the bioprocess technology market are adopting innovative technological products, exemplified by the introduction of Livit Flex, to gain a competitive edge. Livit Flex, launched by Getinge, a Sweden-based healthcare company in December 2022, is an intuitive system for bioprocess control designed to accelerate research and development (R&D) processes for pharmaceuticals and biotech products. Livit Flex offers flexibility, customization, simplicity, and time and cost-efficiency for process optimization. Equipped with smart sensor technology and easy-to-use software functionalities, it enables users to quickly set up parallel experiments and monitor all data from one central location. Configured for single or dual control systems for single-use or multi-use bioreactors, Livit Flex optimizes laboratory bench space. This focus on technological innovation is contributing to the competitive advantage of major companies in the bioprocess technology market.

Prominent companies in the bioprocess technology market are actively pursuing innovation in technological advancements, exemplified by the introduction of the custom organoid line expansion service, to secure a competitive edge. The custom organoid line expansion service involves utilizing proprietary bioreactor and bioprocess technology to scale up the production of organoids. Molecular Devices LLC, a US-based research and development company, launched the custom organoid line expansion service in July 2023. This service is designed to assist researchers in screening thousands to tens of thousands of drug candidates in parallel on organoids from the same source. It plays a crucial role in supporting next-generation drug discovery research, enabling the development of more efficient, reproducible, and scalable patient-derived organoids (PDOs).

In April 2021, Scientific Industries, Inc., a US-based manufacturing company specializing in laboratory equipment and instruments, acquired Aquila Biolabs GmbH for an undisclosed amount. This acquisition is aimed at strengthening Scientific Industries, Inc.'s leadership role in bioprocessing technologies. Additionally, the acquisition brings new skilled professionals into the fold and expands the company's geographic presence into the European market. It further enhances the existing pipeline of advanced sensors and data analytics tools for Scientific Industries, Inc. Aquila Biolabs GmbH, based in Germany, is a technology company providing state-of-the-art data analytics software for bioprocessing applications. This strategic acquisition underscores the commitment of major companies to advancing their capabilities in the dynamic field of bioprocess technology.

Major companies operating in the bioprocess technology market report are Sartorius AG, Danaher Corporation, Thermo Fisher Scientific Inc., Lonza Group AG, F. Hoffmann-La Roche Ltd., Becton Dickinson and Company, Merck KGa, GE Healthcare, Eppendorf AG, Bio-Rad Laboratories, Alere Inc., Fujifilm Healthcare Americas Corporation, Catalent Inc., Asahi Kasei Medical America Inc., Advanced Instruments LLC, Nova Biomedical Corporation, MilliporeSigma, Repligen Corporation, Danaher Corporation, PerkinElmer Inc., Applikon Biotechnology, New Brunswick Scientific Co. Inc., Avid Bioservices, ZETA Holding GmbH, Meissner Filtration Products, ABL Europe, ARTeSYN Biosolutions, Charles River Laboratories, Parker Hannifin Corporation, Shimadzu Corporation, 3M, Eppendorf Biochip Systems, Fermenter Bioreactor, YMC Europe GmbH, Solaris Biotechnology Srl, Aber Instruments, Cytiva.

North America was the largest region in the bioprocess technology market in 2023. Asia-Pacific is expected to be the fastest-growing region in the bioprocess technology market report during the forecast period. The regions covered in the bioprocess technology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the bioprocess technology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary categories of bioprocess technologies include cell culture, cell expansion, flow cytometry, cell line development, and virus infiltration. Cell culture denotes the controlled growth and preservation of cells in a laboratory setting, often utilizing bioprocessing techniques to manufacture biologics at scale for research, clinical investigations, and commercial applications. These technologies find diverse applications in biopharmaceuticals, specialty products, industrial chemicals, and environmental management, and cater to a range of end-users such as hospitals, research laboratories, and medical institutions.

The bioprocess technology market research report is one of a series of new reports that provides bioprocess technology market statistics, including bioprocess technology industry global market size, regional shares, competitors with a bioprocess technology market share, detailed bioprocess technology market segments, market trends, and opportunities, and any further data you may need to thrive in the bioprocess technology industry. This bioprocess technology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.